Skip to content
Loading...
SynAct Pharma logo
  • About
    • Management
    • Board of Directors
    • Advisory Board
    • History
    • Governance
      • General Meetings
      • Governance reports
      • Board Committees
      • Nomination Committee
      • Articles of Association
      • Auditor
    • Code of Conduct
    • Career
  • Our Science
    • Focus Areas
      • Autoimmune and Inflammatory Diseases
      • Host-Directed Therapy – Viral Infections
    • Our Medicines
      • Oral Drugs
      • Peptides
    • Synact Wiki
  • Diseases
    • Rheumatoid Arthritis
    • Nephrotic Syndrome
    • Polymyalgia Rheumatica
    • Dengue Fever
    • COVID-19
  • Development Program
    • Resomelagon
      • Inflammatory and Autoimmune Diseases
        • RA: The BEGIN Study
        • RA: The EXPAND Study
        • RA: The RESOLVE Study
        • RA: The ADVANCE Study
        • iMN: SynAct-CS003
      • Host-Directed Therapy in Viral Infections
        • COVID-19: RESOVIR-1
        • Dengue Fever: RESOVIR-2
    • TXP-11
  • Investors
    • Message from the CEO
    • Investment Highlights
    • Financial Reports
    • The Share
      • Share capital
    • Ownership Structure
    • Board and Management Holdings
    • Analysts
    • Presentations
    • Calendar
    • Prospectus and Rights Issues
  • News & Media
    • News and Press Releases
    • SynAct in the Media
    • Slide Decks and Presentations
    • Image Bank
  • ENG
  • SVE

Extraordinary General Meeting November 2025

November 27, 2025

An Extraordinary General Meeting was held on Thursday, 27 November 2025 at 9.30 a.m at MAQS Advokatbyrå’s premises on Stureplan 19 in Stockholm, Sweden.

Documents

  • Protokoll extra bolagsstämma 27 november 2025 November 27, 2025 - Swedish
  • Press release - Report from the Extraordinary General Meeting of SynAct Pharma AB November 27, 2025 - English
  • Notice to Extraordinary general meeting in November 2025 October 29, 2025 - English
  • Proxy form - EGM 2025 October 30, 2025
  • Terms and conditions of warrants of series ESOP 2025
  • Report by the Board of Directors in Accordance With Chapter 14, Section 8 and Chapter 19, Section 24 of the Swedish Companies Act (2005:551) November 27, 2025 - English
  • Report by the Board of Directors in Accordance With Chapter 19, Section 22 of the Swedish Companies Act (2005:551) November 27, 2025 - English
  • Revisorns yttrande enligt 19 kap. 24 § aktiebolagslagen (2005:551) November 27, 2025 - Swedish
About
  • Management
  • Board of Directors
  • Advisory Board
  • History
  • Governance
    • General Meetings
    • Governance reports
    • Board Committees
    • Nomination Committee
    • Articles of Association
    • Auditor
  • Code of Conduct
  • Career

SynactPharma-white

Advancing medicine trough
melanocortin activation

SynAct Pharma AB (publ)
Scheelevägen 2
SE-223 63 Lund
Sweden

Synact Pharma ApS
Dronninggårds Alle 136
2840 Holte
Denmark

  • About
  • Our Science
  • Diseases
  • Development Program
  • Investors
  • News & Media
  • Privacy Policy
  • Cookies
  • Get the latest news follow us on Linkedin

© 2025 SynAct Pharma AB. All right reserved.